Search

CN-121754641-B - Application of Eppin protein in preparation of liver cancer treatment drugs

CN121754641BCN 121754641 BCN121754641 BCN 121754641BCN-121754641-B

Abstract

The invention discloses an application of Eppin protein in preparing a liver cancer therapeutic drug, and belongs to the technical field of biological medicines. The amino acid sequence of the Eppin protein is shown as SEQ ID No.1, is a Kunitz serine protease inhibitor which is identified from pearl powder for the first time, has excellent anti-liver cancer potential, can remarkably inhibit proliferation, cycle progress, migration, invasion and other aspects of liver cancer cells and promote apoptosis of the liver cancer cells, can be used for preparing liver cancer therapeutic drugs, and promotes development of the pharmaceutical industry.

Inventors

  • LUO WEN
  • JIN CAN

Assignees

  • 绍兴文理学院

Dates

Publication Date
20260508
Application Date
20260303

Claims (8)

  1. 1. The application of the Eppin protein in preparing a liver cancer therapeutic drug is characterized in that the amino acid sequence of the Eppin protein is shown as SEQ ID No. 1.
  2. 2. The application of Eppin protein in preparing a liver cancer therapeutic drug according to claim 1, wherein the cDNA sequence of the Eppin protein is shown in SEQ ID No. 2.
  3. 3. The use of Eppin protein according to claim 1 for preparing a medicament for treating liver cancer, wherein the Eppin protein is Kunitz serine protease inhibitor extracted from pearl powder.
  4. 4. The use of Eppin protein according to claim 1 for preparing a medicament for treating liver cancer, wherein the medicament for treating liver cancer is a medicament for inhibiting proliferation of liver cancer cells.
  5. 5. The use of Eppin protein according to claim 1 for preparing a medicament for treating liver cancer, wherein the medicament for treating liver cancer is a medicament for inhibiting migration of liver cancer cells.
  6. 6. The use of Eppin protein according to claim 1 for preparing a medicament for treating liver cancer, wherein the medicament for treating liver cancer is a medicament for inhibiting invasion of liver cancer cells.
  7. 7. The use of Eppin protein according to claim 1 for preparing a medicament for treating liver cancer, wherein the medicament for treating liver cancer is a medicament for inducing apoptosis of liver cancer cells.
  8. 8. The use of Eppin protein according to claim 1 for preparing a medicament for treating liver cancer, wherein the medicament for treating liver cancer is a medicament for inhibiting the progress of liver cancer cell cycle.

Description

Application of Eppin protein in preparation of liver cancer treatment drugs Technical Field The invention relates to the technical field of biological medicines, in particular to an application of Eppin protein in preparing a liver cancer therapeutic drug. Background Hepatocellular carcinoma (HCC) is one of the most common high-morbidity and high-mortality malignancies, whose occurrence usually involves a lengthy process of persistent inflammatory lesions, necrosis and fibrosis deposition, and the exploration of its therapeutic strategies has always been a major challenge in the field of tumor research. Current treatments for hepatocellular carcinoma include surgical resection, liver transplantation, local ablation, arterial chemoembolization, targeted therapy, immunotherapy, and the like. In recent decades, although these therapeutic approaches are continuously advanced, there are still some problems of low early diagnosis rate, high recurrence rate, difficult prognosis and lack of therapeutic targets. On one hand, radical means such as surgical excision, liver transplantation and the like are only suitable for early patients, and the postoperative recurrence rate is high, on the other hand, late patients are generally insensitive to traditional radiotherapy and chemotherapy, and although the treatment of a system represented by a molecular targeted drug and an immune checkpoint inhibitor improves the treatment effect of late liver cancer, the overall response rate is still not ideal, and adverse reaction and drug resistance problems exist. The development of high-efficiency low-toxicity anti-liver cancer lead compounds or novel treatment strategies from natural products becomes a hot spot of current research. Pearl powder, which is a member of the traditional Chinese medicine treasury, has been used for treating symptoms such as palpitation, insomnia, convulsion, epilepsy, conjunctival congestion, nebula, unhealed sores and ulcers, skin spots and the like, but the pharmacological effect of the pearl powder on the drug effect has not been fully elucidated. If the medicine for treating liver cancer can be extracted from the pearl powder, the research and development blank of the existing natural product anti-liver cancer medicine is filled, and the medicine has important theoretical significance and clinical value. Disclosure of Invention The invention aims to overcome the defects of the prior art and provides the application of the Eppin protein in preparing medicaments for treating liver cancer. In order to achieve the above purpose, the present invention adopts the following technical scheme: the amino acid sequence of the Eppin protein is shown as SEQ ID No. 1. Further, the cDNA sequence of the Eppin protein is shown as SEQ ID No. 2. Further, the Eppin protein is a Kunitz serine protease inhibitor extracted from pearl powder. Further, the liver cancer treatment drug is a drug for inhibiting proliferation of liver cancer cells. Further, the liver cancer treatment drug is a drug for inhibiting migration of liver cancer cells. Further, the liver cancer treatment drug is a drug for inhibiting invasion of liver cancer cells. Further, the liver cancer treatment drug is a drug for inducing apoptosis of liver cancer cells. Further, the liver cancer treatment drug is a drug for inhibiting the progress of liver cancer cell cycle. In summary, the invention has the following beneficial effects: The invention starts with the functional protein Eppin (a Kunitz serine protease inhibitor) identified from pearl powder for the first time, systematically confirms the multi-target antitumor activity effect (including proliferation inhibition, apoptosis induction, retardation cycle and migration invasion inhibition) of the Eppin protein on liver cancer cells Huh-7 cells through in vitro experiments, further confirms the remarkable inhibition effect of the Eppin protein on liver cancer cells in living environment (can promote the occurrence of large-scale coagulation necrosis and obvious apoptosis of tumor tissues and induce the large-scale disintegration of the tumor tissues) through in vivo animal experiments, not only provides a vital modern scientific basis for the traditional efficacy of pearl liver calming and yang suppressing, but also promotes the modernization of traditional Chinese medicines and lays a key preclinical experimental foundation for developing Eppin into a novel anti-liver cancer therapeutic drug derived from natural products. Drawings FIG. 1is a diagram of bioinformatics analysis of Eppin (in the diagram, (A) cDNA sequence and encoded amino acid sequence of Eppin: framed initiation codon and termination codon, double underlined polyadenylation signal, single underlined N-terminal signal peptide (amino acid positions 1-24); (B) schematic domain diagram of Eppin); FIG. 2 shows the result of Huh-7 cell survival test after treatment with different Eppin protein concentrations : p<0.01); FIG. 3 is a graph